Real-Life Chronic Rhinosinusitis Outcome Registry

What this Trial Is About

Researchers are conducting an observational study to collect long-term data from adults diagnosed with chronic rhinosinusitis who attend specialist care centers across Europe. The study aims to better understand the burden of uncontrolled disease, its impact on quality of life and productivity, and how disease severity and related conditions affect these outcomes. It also seeks to identify patients who may benefit from type 2 targeted biologic therapy and to evaluate treatment effectiveness and response markers, as well as to study the societal costs related to chronic rhinosinusitis and its treatment. Participants will use the Galenus Health digital platform, which includes a mobile app for patients and an online dashboard for physicians, to provide data in real-life settings. This data will be centralized in a pseudonymized database forming the Chronic RhinoSinusitis Outcome Registry. The study involves ongoing registration of symptoms, healthcare use, medication intake, and disease severity over time. Participants will be monitored through regular assessments of symptom severity, including facial pain, impaired smell, nasal blockage, and other related symptoms, as well as quality of life measures and healthcare utilization. Data on blood eosinophil counts, serum IgE, nasal polyp scores, and imaging scores will also be collected. The primary outcome is symptom severity over one year, with multiple secondary outcomes covering disease impact, work and school productivity, hospitalizations, and medication use. The total participation length varies by individual involvement and follow-up.

Real-Life Chronic Rhinosinusitis Outcome Registry